Altered Gut Microbiome in Patients With Dermatomyositis.
Altered Gut Microbiome in Patients With Dermatomyositis.
复制标题
DOI：
10.1002/acr2.11436
复制
发表时间：
2022-08
影响因子：
3.4
通讯作者：
中科院分区：
文献类型：
--
作者：
本研究的目的是比较皮肌炎（DM）患者和健康对照（HC）的微生物组成，并确定微生物改变是否与DM的临床表现相关。对来自DM和HC患者的粪便样本进行16 S核糖体RNA基因测序。比较了DM和HC受试者之间的微生物组成和多样性，并与几个DM特异性临床变量（包括肌炎特异性自身抗体（MSA））相关。鉴定了与临床特征相关的不同丰度的微生物分类群和基因，并使用预测的宏基因组学进行功能分析。使用24小时饮食回忆评估饮食摄入量。分析了36例DM和26例HC患者的粪便微生物组。与HC相比，DM患者的微生物多样性倾向于较低。较高的医生整体损伤评分与DM患者较低的微生物多样性显著相关。与HC相比，间质性肺病（ILD）相关MSA（抗合成酶抗体（ab）、抗黑色素瘤分化相关蛋白5 ab，n = 12）患者的微生物组成存在显著差异，微生物多样性较低。差异丰度测试证明了ILD-MSA亚组中独特的分类学特征，预测性宏基因组学鉴定了许多代谢途径中的功能改变。在ILD-MSA组中，变形菌相对丰度的显著增加与参与脂多糖合成和转运的多种途径呈正相关。与HC相比，DM患者，尤其是ILD相关MSA患者的微生物多样性较低，分类组成不同。需要进一步的研究来验证我们的发现，并阐明将肠道微生物组与DM的临床和病理特征联系起来的特定发病机制。
The study objective was to compare the microbial composition of patients with dermatomyositis (DM) and healthy controls (HCs) and determine whether microbial alterations are associated with clinical manifestations of DM. The 16S ribosomal RNA gene sequencing was performed on fecal samples from patients with DM and HCs. Microbial composition and diversity were compared between subjects with DM and HCs and in association with several DM‐specific clinical variables, including myositis‐specific autoantibodies (MSAs). Differentially abundant microbial taxa and genes associated with clinical characteristics were identified, and functional analysis was performed using predicted metagenomics. Dietary intake was assessed using a 24‐hour dietary recall. The fecal microbiome of 36 patients with DM and 26 HCs were analyzed. Patients with DM trended toward lower microbial diversity compared with HCs. The higher physician global damage score was significantly correlated with the lower microbial diversity in patients with DM. Patients with interstitial lung disease (ILD)‐associated MSA (antisynthetase antibody (ab), anti‐melanoma differentiation‐associated protein 5 ab, n = 12) had significant differences in microbial composition and lower microbial diversity compared with HCs. Differential abundance testing demonstrated a unique taxonomic signature in the ILD‐MSA subgroup, and predictive metagenomics identified functional alterations in a number of metabolic pathways. A significant increase in the relative abundance of Proteobacteria was positively correlated with multiple pathways involved in lipopolysaccharide synthesis and transport in the ILD‐MSA group. Patients with DM, particularly with ILD‐associated MSAs, have lower microbial diversity and a distinct taxonomic composition compared with HCs. Further studies are needed to validate our findings and elucidate specific pathogenetic mechanisms that link the gut microbiome to clinical and pathological features of DM.